Associations of insulin resistance and adiponectin with mortality in women with breast cancer

Journal of Clinical Oncology

Volumn 29, Issue 1, 2011, Pages 32-39

  Duggan, Catherine ^a   Irwin, Melinda L ^a   Xiao, Liren ^a   Henderson, Katherine D ^a   Smith, Ashley Wilder ^a   Baumgartner, Richard N ^a   Baumgartner, Kathy B ^a   Bernstein, Leslie ^a   Ballard Barbash, Rachel ^a   McTiernan, Anne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTINEOPLASTIC AGENT; GLUCOSE; INSULIN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; EATING; FEMALE; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HEALTH; HOMEOSTASIS MODEL ASSESSMENT SCORE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCORING SYSTEM;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79951976645     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.4473     Document Type: Article

References (60)

1. Majed B, Moreau T, Asselain B: Overweight, obesity and breast cancer prognosis: Optimal body size indicator cut-points. Breast Cancer Res Treat 115:193-203, 2009
2. Enger SM, Greif JM, Polikoff J, et al: Body weight correlates with mortality in early-stage breast cancer. Arch Surg 139:954-958, 2004
3. Petrelli JM, Calle EE, Rodriguez C, et al: Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 13:325-332, 2002 (Pubitemid 34553513)
4. Borugian MJ, Sheps SB, Kim-Sing C, et al: Waist-to-hip ratio and breast cancer mortality. Am J Epidemiol 158:963-968, 2003 (Pubitemid 37413395)
5. Caan BJ, Kwan ML, Hartzell G, et al: Pre-diagnosis body mass index, post-diagnosis weight change, and prognosis among women with early stage breast cancer. Cancer Causes Control 19:1319-1328, 2008
6. Abrahamson PE, Gammon MD, Lund MJ, et al: General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev 15:1871-1877, 2006
7. Hebert JR, Augustine A, Barone J, et al: Weight, height and body mass index in the prognosis of breast cancer: Early results of a prospective study. Int J Cancer 42:315-318, 1988
8. Matthews DR, Hosker JP, Rudenski AS, et al: Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985 (Pubitemid 15018832)
9. Lawlor DA, Smith GD, Ebrahim S: Hyperinsulinaemia and increased risk of breast cancer: Findings from the British Women's Heart and Health Study. Cancer Causes Control 15:267-275, 2004 (Pubitemid 38988035)
10. Muti P, Quattrin T, Grant BJ, et al: Fasting glucose is a risk factor for breast cancer: A prospective study. Cancer Epidemiol Biomarkers Prev 11:1361-1368, 2002 (Pubitemid 35340370)
11. Del Giudice ME, Fantus IG, Ezzat S, et al: Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47:111-120, 1998 (Pubitemid 28046082)
12. Gunter MJ, Hoover DR, Yu H, et al: Insulin, insulin-like growth factor-I, and risk of breast cancer in post-menopausal women. J Natl Cancer Inst 101:48-60, 2009
13. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002 (Pubitemid 34032594)
14. Pasanisi P, Berrino F, De Petris M, et al: Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119:236-238, 2006
15. Ryan AS, Nicklas BJ, Berman DM, et al: Adiponectin levels do not change with moderate dietary induced weight loss and exercise in obese postmenopausal women. Int J Obes Relat Metab Disord 27:1066-1071, 2003 (Pubitemid 37059612)
16. Chen DC, Chung YF, Yeh YT, et al: Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 237:109-114, 2006
17. Körner A, Pazaitou-Panayiotou K, Kelesidis T, et al: Total and high-molecular-weight adiponectin in breast cancer: In vitro and in vivo studies. J Clin Endocrinol Metab 92:1041-1048, 2007 (Pubitemid 46465681)
18. Mantzoros C, Petridou E, Dessypris N, et al: Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102-1107, 2004 (Pubitemid 38368397)
19. Miyoshi Y, Funahashi T, Kihara S, et al: Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9:5699-5704, 2003 (Pubitemid 37499493)
20. McTiernan A, Rajan KB, Tworoger SS, et al: Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21:1961-1966, 2003
21. Deary IJ: Effects of Hypoglycaemia on Cognitive Function. London, United Kingdom, Edward Arnold, 1993, pp 80-92
22. UK Hypoglycaemia Study Group: Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration. Diabetologia 50:1140-1147, 2007
23. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
24. Lagakos SW: The challenge of subgroup analyses: Reporting without distorting. N Engl J Med 354:1667-1669, 2006
25. Goodwin P, Ennis M, Pritchard K, et al: Fasting insulin predicts distant disease free survival (DDFS) and overall survival (OS) in women with operable breast cancer (T1-3, N0-1, M0) who are receiving standard adjuvant therapy. Proc Am Soc Clin Oncol 19:69a, 2000 (abstr 272)
26. Novosyadlyy R, Lann DE, Vijayakumar A, et al: Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 70:741-751, 2010
27. Frasca F, Pandini G, Vigneri R, et al: Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis 17:73-89, 2003 (Pubitemid 38180810)
28. Chappell J, Leitner JW, Solomon S, et al: Effect of insulin on cell cycle progression in MCF-7 breast cancer cells: Direct and potentiating influence. J Biol Chem 276:38023-38028, 2001
29. Harvie M, Hooper L, Howell AH: Central obesity and breast cancer risk: A systematic review. Obes Rev 4:157-173, 2003 (Pubitemid 36950578)
30. Calle E, Kaaks R: Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591, 2004 (Pubitemid 39025053)
31. Renehan AG, Frystyk J, Flyvbjerg A: Obesity and cancer risk: The role of the insulin-IGF axis. Trends Endocrinol Metab 17:328-336, 2006 (Pubitemid 44397568)
32. Renehan AG, Roberts DL, Dive C: Obesity and cancer: Pathophysiological and biological mechanisms. Arch Physiol Biochem 114:71-83, 2008 (Pubitemid 351998746)
33. Reference deleted
34. Tian YF, Chu CH, Wu MH, et al: Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer 14:669-677, 2007
35. Tworoger SS, Eliassen AH, Kelesidis T, et al: Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab 92:1510-1516, 2007 (Pubitemid 46556432)
36. Barb D, Williams CJ, Neuwirth AK, et al: Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. Am J Clin Nutr 86:s858-s866, 2007
37. Weyer C, Funahashi T, Tanaka S, et al: Hypoadiponectinemia in obesity and type 2 diabetes: Close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001
38. Matsubara M, Maruoka S, Katayose S: Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 147:173-180, 2002
39. Delporte ML, Brichard SM, Hermans MP, et al: Hyperadiponectinaemia in anorexia nervosa. Clin Endocrinol (Oxf) 58:22-29, 2003 (Pubitemid 36098844)
40. Brichard SM, Delporte ML, Lambert M: Adipocytokines in anorexia nervosa: A review focusing on leptin and adiponectin. Horm Metab Res 35:337-342, 2003 (Pubitemid 37102677)
41. Arita Y, Kihara S, Ouchi N, et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999 (Pubitemid 29299050)
42. Stolzenberg-Solomon RZ, Weinstein S, Pollak M, et al: Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol 168:1047-1055, 2008
43. Wei EK, Giovannucci E, Fuchs CS, et al: Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer Inst 97:1688-1694, 2005 (Pubitemid 41672235)
44. Gavrila A, Chan JL, Yiannakouris N, et al: Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: Cross-sectional and interventional studies. J Clin Endocrinol Metab 88:4823-4831, 2003 (Pubitemid 37357532)
45. Fenton JI, Birmingham JM, Hursting SD, et al: Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+ colon epithelial cells. Int J Cancer 122:2437-2445, 2008 (Pubitemid 351590475)
46. Pfeiler GH, Buechler C, Neumeier M, et al: Adiponectin effects on human breast cancer cells are dependent on 17-beta estradiol. Oncol Rep 19:787-793, 2008 (Pubitemid 351330450)
47. Kang JH, Lee YY, Yu BY, et al: Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 28:1263-1269, 2005
48. Wang Y, Lam JB, Lam KS, et al: Adiponectin modulates the glycogen synthase kinase-3beta/ beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66:11462-11470, 2006 (Pubitemid 46009979)
49. Grossmann ME, Nkhata KJ, Mizuno NK, et al: Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 98:370-379, 2008 (Pubitemid 351161253)
50. Ligibel JA, Campbell N, Partridge A, et al: Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 26:907-912, 2008 (Pubitemid 351398083)
51. Simpson KA, Singh MA: Effects of exercise on adiponectin: A systematic review. Obesity (Silver Spring) 16:241-256, 2008 (Pubitemid 351271902)
52. Ligibel JA, Giobbie-Hurder A, Olenczuk D, et al: Impact of a mixed strength and endurance exercise intervention on levels of adiponectin, high molecular weight adiponectin and leptin in breast cancer survivors. Cancer Causes Control 20:1523-1528, 2009
53. Zhou G, Myers R, Li Y, et al: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001 (Pubitemid 32995375)
54. Evans JM, Donnelly LA, Emslie-Smith AM, et al: Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305, 2005 (Pubitemid 40813563)
55. Libby G, Donnelly LA, Donnan PT, et al: New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625, 2009
56. Landman GW, Kleefstra N, van Hateren KJ, et al: Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33:322-326, 2010
57. Jiralerspong S, Palla SL, Giordano SH, et al: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302, 2009
58. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, et al: If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials. J Clin Oncol 27:e207-e209; 2009
59. Goodwin PJ, Ligibel JA, Stambolic V: Metformin in breast cancer: Time for action. J Clin Oncol 27:3271-3273, 2009
60. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, et al: Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol Biomarkers Prev 18:701-705, 2009